Pfizer Inc. $PFE Shares Sold by Rahlfs Capital LLC

Rahlfs Capital LLC lowered its holdings in Pfizer Inc. (NYSE:PFE) by 3.8% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 38,453 shares of the biopharmaceutical company’s stock after selling 1,500 shares during the quarter. Rahlfs Capital LLC’s holdings in Pfizer were worth $974,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Clarity Asset Management Inc. acquired a new stake in shares of Pfizer in the fourth quarter worth $27,000. Gould Capital LLC increased its stake in shares of Pfizer by 97.2% in the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 493 shares during the period. GKV Capital Management Co. Inc. acquired a new stake in shares of Pfizer in the first quarter worth $27,000. North Capital Inc. acquired a new stake in shares of Pfizer in the first quarter worth $28,000. Finally, Bayforest Capital Ltd acquired a new stake in shares of Pfizer in the first quarter worth $28,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on PFE. UBS Group increased their price objective on shares of Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 30th. Wolfe Research raised their price target on shares of Pfizer from $22.00 to $23.00 and gave the company an “underperform” rating in a research report on Wednesday, April 30th. Leerink Partners dropped their price target on shares of Pfizer from $28.00 to $26.00 and set a “market perform” rating on the stock in a research report on Wednesday, April 30th. Berenberg Bank dropped their price target on shares of Pfizer from $28.00 to $25.00 and set a “hold” rating on the stock in a research report on Thursday, May 29th. Finally, Redburn Atlantic dropped their price target on shares of Pfizer from $29.00 to $27.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 30th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $28.12.

Pfizer Stock Up 0.3%

Shares of NYSE PFE opened at $25.8250 on Friday. The company’s 50-day simple moving average is $24.70 and its 200-day simple moving average is $24.42. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $30.43. The firm has a market cap of $146.83 billion, a price-to-earnings ratio of 13.74, a price-to-earnings-growth ratio of 0.92 and a beta of 0.52. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same quarter last year, the business earned $0.60 earnings per share. The company’s revenue for the quarter was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a yield of 6.7%. Pfizer’s payout ratio is presently 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.